3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Myeloid
1
CNS
1
Conditions
Glioblastoma
11
Brain Neoplasms
11
Gliosarcoma
9
Neuroblastoma
5
Astrocytoma
5
Oligodendroglioma
4
Glioma
4
Carcinoma, Renal Cell
4
Sarcoma, Ewing
3
Sarcoma
3
Rhabdomyosarcoma
3
Rhabdoid Tumor
3
Recurrence
3
Neoplasms, Germ Cell and Embryonal
3
Central Nervous System Neoplasms
3
Breast Neoplasms
3
Wilms Tumor
2
Prostatic Neoplasms
2
Osteosarcoma
2
Neurofibromatosis 2
2
Neurofibromatosis 1
2
Neoplasms
2
Melanoma
2
Medulloblastoma
2
Ependymoma
2
Carcinoma, Hepatocellular
2
Vestibulocochlear Nerve Diseases
1
Uterine Cervical Neoplasms
1
Urologic Neoplasms
1
Urinary Bladder Neoplasms
1
Interventions
Temozolomide
6
Cyclophosphamide
5
Magnetic Resonance Spectroscopy
4
Carboplatin
4
etoposide phosphate
3
Thiotepa
3
Surgical Procedures, Operative
3
Irinotecan
3
Filgrastim
3
Automobiles
3
temsirolimus
2
fludarabine
2
entinostat
2
Vincristine
2
Radiotherapy, Conformal
2
Proton Therapy
2
Peripheral Blood Stem Cell Transplantation
2
Nivolumab
2
Isotretinoin
2
Granulocyte Colony-Stimulating Factor
2
Gadolinium DTPA
2
Etoposide
2
Donepezil
2
Cisplatin
2
Celecoxib
2
Bevacizumab
2
Amplified Fragment Length Polymorphism Analysis
2
2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole
2
trametinib
1
tozuleristide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pinealoma
×
Sirolimus
×
CNS
×
Clear all
NCT02574728
2026-03-02
AflacST1502
Emory University
Phase 2
Active not recruiting
46 enrolled